vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and BUILD-A-BEAR WORKSHOP INC (BBW). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $122.7M, roughly 1.5× BUILD-A-BEAR WORKSHOP INC). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.6%, a 6.7% gap on every dollar of revenue. On growth, BUILD-A-BEAR WORKSHOP INC posted the faster year-over-year revenue change (2.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $1.7M).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Build-A-Bear Workshop, Inc. is an American retailer headquartered in St. Louis, Missouri that sells teddy bears, stuffed animals, and characters. During store visits, customers go through an interactive process where the stuffed animal of their choice is assembled and tailored to their own preferences including varying scents, sounds, looks, and outfits. Build-A-Bear Workshop is the largest chain that operates in this style. The company's slogan was "Where Best Friends Are Made" from 1997–201...
AMPH vs BBW — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $122.7M |
| Net Profit | $24.4M | $8.1M |
| Gross Margin | 46.8% | 53.7% |
| Operating Margin | 19.4% | 8.7% |
| Net Margin | 13.3% | 6.6% |
| Revenue YoY | -1.8% | 2.7% |
| Net Profit YoY | -35.7% | -17.7% |
| EPS (diluted) | $0.51 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $122.7M | ||
| Q3 25 | $191.8M | $124.2M | ||
| Q2 25 | $174.4M | $128.4M | ||
| Q1 25 | $170.5M | $150.4M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $182.4M | — | ||
| Q1 24 | $171.8M | — |
| Q4 25 | $24.4M | $8.1M | ||
| Q3 25 | $17.4M | $12.4M | ||
| Q2 25 | $31.0M | $15.3M | ||
| Q1 25 | $25.3M | $21.7M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $37.9M | — | ||
| Q1 24 | $43.2M | — |
| Q4 25 | 46.8% | 53.7% | ||
| Q3 25 | 51.4% | 57.6% | ||
| Q2 25 | 49.6% | 56.8% | ||
| Q1 25 | 50.0% | 56.6% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 8.7% | ||
| Q3 25 | 13.2% | 12.3% | ||
| Q2 25 | 24.2% | 15.3% | ||
| Q1 25 | 21.9% | 18.3% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | 6.6% | ||
| Q3 25 | 9.0% | 10.0% | ||
| Q2 25 | 17.8% | 11.9% | ||
| Q1 25 | 14.8% | 14.4% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 25.1% | — |
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $0.94 | ||
| Q2 25 | $0.64 | $1.17 | ||
| Q1 25 | $0.51 | $1.61 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $27.7M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $150.6M |
| Total Assets | $1.6B | $326.5M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $27.7M | ||
| Q3 25 | $276.2M | $39.1M | ||
| Q2 25 | $231.8M | $44.3M | ||
| Q1 25 | $236.9M | $27.8M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $150.6M | ||
| Q3 25 | $776.7M | $155.4M | ||
| Q2 25 | $757.5M | $148.7M | ||
| Q1 25 | $751.3M | $139.1M | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | — | ||
| Q2 24 | $713.3M | — | ||
| Q1 24 | $672.4M | — |
| Q4 25 | $1.6B | $326.5M | ||
| Q3 25 | $1.7B | $318.2M | ||
| Q2 25 | $1.6B | $308.3M | ||
| Q1 25 | $1.6B | $290.0M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $8.2M |
| Free Cash FlowOCF − Capex | $24.6M | $1.7M |
| FCF MarginFCF / Revenue | 13.4% | 1.4% |
| Capex IntensityCapex / Revenue | 4.5% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.01× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $37.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $8.2M | ||
| Q3 25 | $52.6M | $4.2M | ||
| Q2 25 | $35.6M | $27.8M | ||
| Q1 25 | $35.1M | $19.5M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $69.1M | — | ||
| Q1 24 | $55.3M | — |
| Q4 25 | $24.6M | $1.7M | ||
| Q3 25 | $47.2M | $793.0K | ||
| Q2 25 | $25.0M | $24.9M | ||
| Q1 25 | $24.4M | $9.8M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 1.4% | ||
| Q3 25 | 24.6% | 0.6% | ||
| Q2 25 | 14.3% | 19.4% | ||
| Q1 25 | 14.3% | 6.5% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 5.3% | ||
| Q3 25 | 2.8% | 2.8% | ||
| Q2 25 | 6.1% | 2.3% | ||
| Q1 25 | 6.3% | 6.5% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 1.01× | ||
| Q3 25 | 3.03× | 0.34× | ||
| Q2 25 | 1.15× | 1.81× | ||
| Q1 25 | 1.39× | 0.90× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BBW
| Direct To Consumer | $112.3M | 92% |
| Commercial Product And Service | $8.9M | 7% |
| International Franchising | $1.5M | 1% |
